Sens. Ron Wyden and Chuck Grassley. Photo: Tom Williams/CQ Roll Call

Senate Finance Committee leaders have asked 5 pharmacy benefit managers to come up to Capitol Hill for a hearing, as a follow-up to the panel's largely anticlimactic sit-down with pharmaceutical CEOs last month.

Why it matters: Pharma used its hearing to point the finger at PBMs. Now they may get a chance to defend themselves and try to shift the political blame back to pharma and its list prices.

Where it stands: Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.) want to hear from Cigna, CVS Caremark, Humana, OptumRx and Prime Therapeutics. Despite the bipartisan tenor of the drug-pricing debate, agreement on actual policy remains hard to come by, at least for now.

  • The House Energy and Commerce Committee will hold a hearing today on several bills designed to enhance competition — including the CREATES Act, which would improve generics' access to product samples.
  • But even those smaller-bore bills are controversial. "They're all partisan bills ... In their present form, they need work," Rep. Greg Walden said.

What we're hearing: As Vitals reported yesterday, President Trump's budget proposal revived a handful of policy ideas worth keeping an eye on as potential sources of compromise, including a new cap on seniors' out-of-pocket drug costs.

  • There's bipartisan interest in such a limit, but big differences on the details. Wyden has proposed a cap of $2,650, while Trump's version would effectively fall closer to $6,350, my colleague Caitlin Owens notes.
  • Grassley says he supports an out-of-pocket limit, but hasn't endorsed a specific plan.

Go deeper: Big Pharma won its last Capitol Hill hearing

Go deeper

Updated 8 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 10:30 a.m. ET: 30,217,420 — Total deaths: 946,847— Total recoveries: 20,554,349Map.
  2. U.S.: Total confirmed cases as of 10:30 a.m. ET: 6,677,516 — Total deaths: 197,682 — Total recoveries: 2,540,334 — Total tests: 91,546,598Map.
  3. Politics: Trump vs. his own administration on virus response.
  4. Health: Massive USPS face mask operation called off The risks of moving too fast on a vaccine.
  5. Business: Unemployment drop-off reverses course 1 million mortgage-holders fall through safety netHow the pandemic has deepened Boeing's 737 MAX crunch.
  6. Education: At least 42% of school employees are vulnerable.
Dan Primack, author of Pro Rata
13 mins ago - Economy & Business

U.S. nutritional supplements retailer takes first step to sell to China’s Harbin Pharma

Illustration: Sarah Grillo/Axios

GNC Holdings, the Pittsburgh-based nutritional supplements retailer, received bankruptcy court approval to sell itself to China’s Harbin Pharma for $770 million, although the deal still faces U.S. political pressures over how GNC customer data is protected.

Why it matters: It's a reminder that the U.S.-China merger mess goes well beyond smartphone apps, with Sen. Marco Rubio asking for a CFIUS review.

Ben Geman, author of Generate
1 hour ago - Energy & Environment

Tallying Trump's climate changes

Reproduced from Rhodium Climate Service; Chart: Axios Visuals

The Trump administration's scuttling or weakening of key Obama-era climate policies could together add 1.8 gigatons of carbon dioxide equivalent to the atmosphere by 2035, a Rhodium Group analysis concludes.

Why it matters: The 1.8 gigatons is "more than the combined energy emissions of Germany, Britain and Canada in one year," per the New York Times, which first reported on the study.